Table IV AMD risk for advanced AMD based on genotype and CEP markers

Odds ratios were determined for advanced AMD risk based on genotype alone or based on the joint effect of genotype plus elevated levels of both CEP markers relative to median control levels (≥19 pmol/ml CEP adducts and ≥1.3 CEP autoantibody titer). Odds ratios and 95% CI involving CEP markers are based on log-transformed concentrations.

AMD risk genotypeGenotype frequency (%)Odds ratio (95% CI)
ControlAdvanced AMDGenotype onlyJoint effect CEP adducts and autoantibodies
Not both elevatedBoth elevated
ARMS2n = 404n = 457
    GG246 (60.9%)151 (33.1%)1.00 (reference)1.00 (reference)2.51 (1.65, 3.83)
    GT143 (35.4%)209 (45.7%)2.38 (1.78, 3.19)2.35 (1.59, 3.49)5.58 (3.62, 8.61)
    TT15 (3.7%)97 (21.2%)10.54 (5.90, 18.82)8.94 (4.23, 18.87)27.74 (10.70, 71.93)
HTRA1n = 229n = 511
    GG134 (58.5%)175 (34.2%)1.00 (reference)1.00 (reference)2.75 (1.68, 4.52)
    GA78 (34.1%)204 (39.9%)2.05 (1.45, 2.89)2.43 (1.56, 3.78)3.79 (2.29, 6.27)
    AA17 (7.4%)132 (25.8%)6.08 (3.50, 10.58)5.84 (2.80, 12.16)12.82 (5.63, 29.21)
CFHn = 381n = 526
    TT161 (42.3%)96 (18.3%)1.00 (reference)1.00 (reference)2.12 (1.26, 3.56)
    TC172 (45.1%)261 (49.6%)2.54 (1.85, 3.50)2.28 (1.49, 3.49)6.28 (3.93, 10.01)
    CC48 (2.6%)169 (32.1%)5.90 (3.92, 8.88)6.74 (3.96, 11.49)10.54 (5.63, 19.73)
C3n = 343n = 509
    CC198 (57.7%)195 (38.3%)1.00 (reference)1.00 (reference)2.72 (1.80, 4.11)
    CG114 (33.2%)190 (37.3%)1.69 (1.25, 2.30)2.13 (1.42, 3.18)4.05 (2.56, 6.39)
    GG31 (9.1%)124 (24.4%)4.06 (2.61, 6.31)5.19 (3.00, 8.97)8.86 (4.15, 18.90)